Multidrug resistance Mediated by P-glycoprotein

P-糖蛋白介导的多药耐药性

• 批准号: 7594770
• 负责人: Antonio Fojo
• 金额: $ 94.31万
• 依托单位: DIVISION OF CLINICAL SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7594770
• 关键词: ABCB1 gene; Accounting; Acetylation; Acute Lymphocytic Leukemia; Adult; Affect; Area; Biological Assay; Brain; Causations; Cell Line; Cell hybridization; Cells; Characteristics; Child; Childhood Acute Lymphocytic Leukemia; Childhood Acute Myeloid Leukemia; Chromatin Structure; Chromosomes; Chromosomes, Human, Pair 7; Clinic; Clinical; Complex; Cultured Cells; Cytotoxic agent; DNA Sequence Rearrangement; Data; Depth; Development; Disease; Disruption; Doctor of Medicine; Drug Exposure; Drug resistance; Drug-sensitive; Educational process of instructing; Epigenetic Process; Event; Formalin; Frequencies; Future; Genbank; Gene Rearrangement; Genes; Genetic; Genetic Transcription; Genomics; Goals; HERVs; Histone Acetylation; Homologous Gene; Human; Hybrid Cells; Hybrids; Impairment; In Vitro; Institution; Investigation; Knock-out; Knockout Mice; Knowledge; Lead; Learning; Length; Location; Lymphoma; Mediating; Modeling; Molecular; Multi-Drug Resistance; Mus; Nature; Nervous system structure; Neurons; Nonhomologous DNA End Joining; Normal tissue morphology; Numbers; Oral; Outcome; P-Glycoprotein; P-Glycoproteins; Patients; Pharmaceutical Preparations; Phenotype; Physiological; Polymerase Chain Reaction; Race; Refractory; Refractory Disease; Regulation; Repetitive Sequence; Research; Research Personnel; Resistance; Role; Sampling; Site; Solid; Structure; Thinking; Toxic effect; Transcript; Translational Research; Untranslated Regions; Wild Type Mouse; Work; base; chemotherapy; drug sensitivity; experience; homologous recombination; in vivo; in vivo Model; interest; leukemia; multi drug transporter; novel; prevent; promoter; research study; resistance mechanism; tissue fixing; tumor

Background: In the field of multidrug resistance mediated by the multidrug transporter, P glycoprotein, which is encoded by the MDR-1 gene, our efforts continue to have a major focus on translational research, while trying to pursue basic investigations that have the potential for future clinical correlations. Since its original description nearly 20 years ago, increased expression of P-glycoprotein (Pgp) has been frequently observed in cell culture models of multidrug resistance and in clinical samples obtained from refractory patients. But while progress has been made, the regulation of Pgp expression is not fully understood. Is MDR-1/Pgp expression in drug selected cells and refractory tumors under similar regulatory control as that in normal tissues, or drug sensitive cells? Our results suggest the answer is no. In all drug resistant cell lines derived from parental cells that do not normally express MDR-1 or express MDR-1 at low levels, the mechanisms regulating MDR-1 expression are acquired and abnormal. Expression from an unrelated, active promoter, proceeding in a normal or an aberrant direction, can control transcription. This occurs principally as a result of a gene rearrangement that leads to capture of MDR-1 by an unrelated promoter. Alternately, aberrant transcription can begin in a region 112 kb 5 prime of MDR-1. Following drug selection this region functions as a promoter. Evidence suggests that an HERV LTR is involved in this aberrant transcription and that acetylation of a nearby sequence may be an important epigenetic event in the activation of this aberrant promoter. Our research goals are to (1) understand the molecular basis of acquired MDR-1 expression; (2) comprehend how/why these changes occur; (3) search for them in clinical samples and (4) devise strategies to reduce or prevent their occurrence. In the clinic, in collaborative studies with Susan Bates, M.D. we continue to conduct trials examining the use of Pgp antagonists as modulators of drug sensitivity. Project Description and Plans: We have identified gene rearrangements as the mechanism responsible for the activation of MDR-1 in a large number of cell lines, and in patient samples. These rearrangements occur randomly and are characterized by the juxtaposition of a transcriptionally active gene 5 prime to MDR-1, thus avoiding disruption of MDR-1 structure. These gene rearrangements leading to activation of MDR-1 represent a mechanism of resistance with the following characteristics: (i) the rearrangement is an acquired phenotype, not detected in parental cells, and (ii) the rearrangement provides a mechanism for activation of MDR-1 in cells that do not express MDR-1 or express MDR-1 at very low levels; this is not a mechanism for over-expression of MDR-1 in a cell that expresses MDR-1 endogenously at significant levels. Additional characteristics include the following: (1) The majority of MDR-1 transcripts in these cells are hybrid mRNAs. (2) Activation occurs by juxtaposing an active promoter 5 prime to MDR-1, and initiating transcription at this promoter. Expression of the non-MDR-1 gene can be readily detected in a variety of cells suggesting the non-MDR-1 gene is constitutively active and has widespread expression. Furthermore, where information has been available for the non-MDR-1 sequences, the residues fused to MDR-1 have been from the 5 prime UTR of the respective genes (3) The rearrangements appear to occur randomly and involve genes found in chromosome 7 and in chromosomes other than 7. The sequences within 7 are found either centromeric or telomeric of MDR-1 (i.e. inversions occur). The breakpoints have been characterized in eight drug resistant cell lines. Rearrangements occurred as a result of either homologous recombination or non-homologous end joining. While the breakpoints appear to be unique, Alu repeats or other commonly occurring repetitive sequences appear to have been involved in the majority of rearrangements. In addition to gene rearrangements that lead to the capture of MDR-1, we have identified a second mechanism of acquired MDR-1 expression: Aberrant transcription from an aberrant promoter located 112 kb 5 prime to the normal start of MDR-1. Early studies examining MDR-1/Pgp expression in cell culture concluded MDR-1 expression was under the control of two promoters designated the upstream and downstream promoters. We now recognize the downstream promoter to be the normal MDR1 promoter. Transcripts containing additional sequences 5 prime of the downstream promoter start residues were assumed to originate at the putative upstream promoter. We discovered that in many of these cases the upstream promoter is actually the promoter of another unrelated gene as described above. However, in several drug resistant cell lines 5 prime RACE found similar 5 prime sequences proximal to residue -194 indicating transcripts in these cell lines shared a similar start site. A GENBANK search found that the 251 bp shared by these resistant cell lines were 112,276 bp 5 prime of the normal start site of MDR-1 transcription. Expression of the 251 bp could not be detected in any parental cell with the exception of ZR-75B cells, nor in 15 normal tissues suggesting expression does not occur under normal circumstances. Further studies have shown that these transcripts are aberrant and that their expression is regulated by nearby genomic sequences that may include a human endogenous retroviral LTR. Expression of this LTR occurs in all cells. However, following drug selection, MDR-1 transcripts begin near this retroviral LTR with transcription in the direction opposite of the usual LTR transcription. Because expression of these aberrant MDR-1 transcripts is found only in drug-resistant cell lines, we conclude that the development of drug resistance or the attendant drug exposure has a role in the activation of this phenomenon. We have also identified in our cell lines and in collaborative studies evidence that some of the transcripts originating at this aberrant promoter may be starting at this location because of changes in chromatin structure in this region. Evidence for this includes data showing increased histone acetylation in this region in drug resistant cells. Our current efforts are directed at further understanding this phenomenon and at developing an assay that can assess this accurately in patient samples, with an emphasis on developing an assay that can be performed using formalin fixed tissue. Do MDR-1 transcripts containing the 251 bp occur clinically? Yes. In 12 of 23 samples from patients with refractory lymphomas, PCR amplification documented hybrid messages containing the 251 bp 5? to MDR-1; similar transcripts were not found in 18 untreated lymphomas. Furthermore, in a subset of the refractory lymphomas, 5 prime RACE found the 5 prime sequences matched the 251 bp, differing only in length. These differences are consistent with multiple start sites, a finding that may be explained by the aberrant nature of transcription. Since this is an acquired aberrancy, the start site may not be as well defined

背景：在由多药转运蛋白 P 糖蛋白（由 MDR-1 基因编码）介导的多药耐药领域，我们的工作继续主要集中在转化研究上，同时努力开展有潜力的基础研究。未来的临床相关性。自从近 20 年前首次被描述以来，在多药耐药细胞培养模型和从难治性患者获得的临床样本中经常观察到 P-糖蛋白 (Pgp) 表达增加。尽管已经取得了进展，但 Pgp 表达的调控尚未完全了解。药物选择细胞和难治性肿瘤中的 MDR-1/Pgp 表达是否受到与正常组织或药物敏感细胞类似的调控控制？我们的结果表明答案是否定的。在所有源自正常不表达MDR-1或低水平表达MDR-1的亲本细胞的耐药细胞系中，调节MDR-1表达的机制是获得性的且异常的。来自不相关的活性启动子的表达，以正常或异常方向进行，可以控制转录。这主要是由于基因重排导致 MDR-1 被不相关的启动子捕获的结果。或者，异常转录可以从 MDR-1 的 112 kb 5 引物区域开始。在药物选择之后，该区域充当启动子。有证据表明，HERV LTR 参与了这种异常转录，并且附近序列的乙酰化可能是该异常启动子激活过程中的重要表观遗传事件。我们的研究目标是（1）了解获得性MDR-1表达的分子基础； (2) 理解这些变化如何/为何发生； (3) 在临床样本中寻找它们，以及 (4) 制定策略来减少或预防它们的发生。在临床上，在与医学博士 Susan Bates 的合作研究中，我们继续进行试验，检验 Pgp 拮抗剂作为药物敏感性调节剂的用途。项目描述和计划：我们已经确定基因重排是在大量细胞系和患者样本中激活 MDR-1 的机制。这些重排是随机发生的，其特点是转录活性基因 5 prime 与 MDR-1 并置，从而避免了 MDR-1 结构的破坏。这些导致 MDR-1 激活的基因重排代表了具有以下特征的耐药机制：（i）重排是一种获得性表型，在亲代细胞中未检测到；（ii）重排提供了 MDR-1 激活的机制。 1 在不表达 MDR-1 或表达水平非常低的 MDR-1 的细胞中；这不是在显着水平内源性表达 MDR-1 的细胞中过度表达 MDR-1 的机制。其他特征包括以下内容： (1) 这些细胞中的大多数 MDR-1 转录物是混合 mRNA。 (2) 通过将活性启动子 5 与 MDR-1 并列并在该启动子处启动转录来发生激活。可以在多种细胞中容易地检测到非MDR-1基因的表达，这表明非MDR-1基因具有组成型活性并且具有广泛表达。 此外，在非 MDR-1 序列的信息可用的情况下，与 MDR-1 融合的残基来自相应基因的 5 素 UTR (3) 重排似乎是随机发生的，涉及在 7 号染色体中发现的基因7号染色体以外的染色体中。7号内的序列被发现是MDR-1的着丝粒或端粒（即发生倒位）。断点已在八种耐药细胞系中得到表征。 重排是由于同源重组或非同源末端连接而发生的。虽然断点似乎是独特的，但 Alu 重复序列或其他常见的重复序列似乎参与了大多数重排。除了导致 MDR-1 捕获的基因重排之外，我们还确定了获得性 MDR-1 表达的第二种机制：从位于 112 kb 5 prime 的异常启动子到 MDR-1 正常起始处的异常转录。检查细胞培养物中 MDR-1/Pgp 表达的早期研究得出结论，MDR-1 表达受到指定为上游和下游启动子的两个启动子的控制。我们现在认识到下游启动子是正常的 MDR1 启动子。含有下游启动子起始残基的附加序列5'的转录本被假定源自推定的上游启动子。我们发现，在许多情况下，上游启动子实际上是另一个不相关基因的启动子，如上所述。然而，在几种耐药细胞系中，5prim RACE 发现靠近残基-194 的相似5prim 序列，表明这些细胞系中的转录物共享相似的起始位点。 GENBANK 搜索发现，这些耐药细胞系共有的 251 bp 是 MDR-1 转录正常起始位点的 112,276 bp 5 引物。除 ZR-75B 细胞外，在任何亲本细胞中均未检测到 251 bp 的表达，在 15 个正常组织中也未检测到该表达，表明在正常情况下不会发生表达。进一步的研究表明，这些转录本是异常的，并且它们的表达受到附近基因组序列的调节，其中可能包括人内源性逆转录病毒LTR。该 LTR 的表达发生在所有细胞中。然而，在药物选择后，MDR-1 转录物在该逆转录病毒 LTR 附近开始转录，其转录方向与通常的 LTR 转录相反。由于这些异常 MDR-1 转录物的表达仅在耐药细胞系中发现，因此我们得出结论，耐药性的发展或随之而来的药物暴露在这种现象的激活中发挥了作用。我们还在我们的细胞系和合作研究中发现证据表明，由于该区域染色质结构的变化，源自该异常启动子的一些转录本可能从该位置开始。这方面的证据包括显示耐药细胞中该区域组蛋白乙酰化增加的数据。我们目前的努力旨在进一步了解这种现象，并开发一种可以在患者样本中准确评估这种现象的测定方法，重点是开发一种可以使用福尔马林固定组织进行的测定方法。临床上是否存在含有 251 bp 的 MDR-1 转录本？是的。在来自难治性淋巴瘤患者的 23 个样本中的 12 个中，PCR 扩增记录了包含 251 bp 5? MDR-1；在 18 例未经治疗的淋巴瘤中没有发现类似的转录本。此外，在难治性淋巴瘤的子集中，5 prime RACE 发现 5 prime 序列与 251 bp 匹配，仅长度不同。这些差异与多个起始位点一致，这一发现可以用转录的异常性质来解释。由于这是一种后天性异常，因此起始位点可能没有明确定义